SCHEMBL27237428

SCHEMBL27237428

COc1ccc(-c2nccc(C(=O)NN=Cc3cc(OC)cc(OC)c3)n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ HDAC6 Q9UBN7 1/20 0.55
▸ MGAM O43451 2/20 0.52
▸ POLB P06746 3/20 0.49
▸ ALDH1A1 P00352 5/20 0.48
▸ HPGD P15428 3/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ HTT P42858 2/20 0.48
▸ MAPT P10636 2/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ AMY1A P0DUB6 1/20 0.47
▸ TP53 P04637 1/20 0.46
▸ MAOB P27338 1/20 0.46
▸ LMNA P02545 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25002984 1.00 KMT2A (0.58) KMT2AMEN1HDAC6MGAMPOLB
SCHEMBL25003168 0.93 HDAC6 (0.51) KMT2AMEN1HDAC6MGAMPOLB
SCHEMBL27237402 0.93 HDAC6 (0.51) KMT2AMEN1HDAC6MGAMPOLB
SCHEMBL27237430 0.93 HDAC6 (0.53) KMT2AMEN1HDAC6MGAMPOLB
SCHEMBL25003164 0.93 HDAC6 (0.53) KMT2AMEN1HDAC6MGAMPOLB
SCHEMBL25002982 0.92 KMT2A (0.52) KMT2AMEN1HDAC6MGAMPOLB
SCHEMBL27237487 0.92 KMT2A (0.52) KMT2AMEN1HDAC6MGAMPOLB
SCHEMBL25002986 0.91 HDAC6 (0.49) KMT2AMEN1HDAC6MGAMPOLB
SCHEMBL25002989 0.91 GCGR (0.50) KMT2AMEN1HDAC6MGAMPOLB
SCHEMBL25002985 0.91 HDAC6 (0.49) KMT2AMEN1HDAC6MGAMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240335420-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV 1.7 AND/OR NAV 1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME AND KITS EUROFARMA LABORATÓRIOS S.A. (BR) 2024-10-10 — — US claimed
EP-4382101-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS Eurofarma Laboratórios S.A. (BR) 2024-06-12 — — EP claimed
CN-118076347-A N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same 欧罗法玛实验室股份公司 2024-05-24 — — CN claimed
US-20240335420-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV 1.7 AND/OR NAV 1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME AND KITS EUROFARMA LABORATÓRIOS S.A. (BR) 2024-10-10 — — US disclosed
EP-4382101-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS Eurofarma Laboratórios S.A. (BR) 2024-06-12 — — EP disclosed
CN-118076347-A N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same 欧罗法玛实验室股份公司 2024-05-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335420-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV 1.7 AND/OR NAV 1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME AND KITS SCN1A, SCN1B, CACNA1B KMT2A 2472/4885MEN1 2198/4885HDAC6 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback